LIVMARLI

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Israel, Italy, Lithuania, Romania, United States

Active ingredients

The drug LIVMARLI contains one active pharmaceutical ingredient (API):

1 Maralixibat UNII V78M04F0XC - MARALIXIBAT CHLORIDE

Maralixibat is a minimally absorbed, reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT). Maralixibat acts locally in the distal ileum to decrease the reuptake of bile acids and increase the clearance of bile acids through the colon, reducing the concentration of bile acids in the serum. Read about Maralixibat

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LIVMARLI Oral solution	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A05AX04		A Alimentary tract and metabolism → A05 Bile and liver therapy → A05A Bile therapy → A05AX Other drugs for bile therapy
Discover more medicines within A05AX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3038587
Country: FR	Base de données publique des médicaments	Identifier(s): 61952616
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9219
Country: IT	Agenzia del Farmaco	Identifier(s): 050418019
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1096065
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69366001
Country: US	FDA, National Drug Code	Identifier(s): 79378-110